$KYMR
Kymera Therapeutics, Inc.

2023 Q2 Form 10-Q Financial Statement

#000095017023017462 Filed on May 04, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $16.51M $9.466M $9.622M
YoY Change 43.42% -1.62% -48.55%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $14.13M $12.57M $10.61M
YoY Change 28.08% 18.41% 79.54%
% of Gross Profit
Research & Development $45.77M $42.23M $35.94M
YoY Change 10.83% 17.48% 38.45%
% of Gross Profit
Depreciation & Amortization $900.0K $879.0K $687.0K
YoY Change 28.57% 27.95% 41.65%
% of Gross Profit
Operating Expenses $59.90M $54.79M $46.56M
YoY Change 14.47% 17.69% 46.07%
Operating Profit -$43.38M -$45.33M -$36.93M
YoY Change 6.3% 22.72% 180.45%
Interest Expense $4.584M $4.398M $249.0K
YoY Change 728.93% 1666.27% 176.67%
% of Operating Profit
Other Income/Expense, Net $4.584M $4.398M $249.0K
YoY Change 728.93% 1666.27% 164.89%
Pretax Income -$38.80M -$40.93M -$36.68M
YoY Change -3.62% 11.57% 180.46%
Income Tax $100.0K $0.00 $0.00
% Of Pretax Income
Net Earnings -$38.80M -$40.93M -$36.68M
YoY Change -3.62% 11.57% 180.57%
Net Earnings / Revenue -234.96% -432.37% -381.25%
Basic Earnings Per Share -$0.67 -$0.70 -$0.71
Diluted Earnings Per Share -$0.67 -$0.70 -$710.2K
COMMON SHARES
Basic Shares Outstanding 55.31M 55.18M 51.70M
Diluted Shares Outstanding 58.33M 58.19M 51.65M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $367.6M $396.9M $420.8M
YoY Change -6.3% -5.69% 26.18%
Cash & Equivalents $52.39M $50.15M $33.73M
Short-Term Investments $315.2M $346.7M $387.1M
Other Short-Term Assets $13.71M $11.35M $9.307M
YoY Change 69.4% 21.98% 69.22%
Inventory
Prepaid Expenses
Receivables $4.122M $3.320M $1.263M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $385.4M $411.6M $431.4M
YoY Change -4.31% -4.6% 26.58%
LONG-TERM ASSETS
Property, Plant & Equipment $27.49M $17.43M $11.76M
YoY Change 115.67% 48.24% -42.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $104.8M $119.0M $102.5M
YoY Change 16.16% 16.14% 0.86%
Other Assets $2.802M $3.155M $2.022M
YoY Change 15.45% 56.03% 26.38%
Total Long-Term Assets $196.5M $202.4M $131.7M
YoY Change 62.9% 53.67% 6.36%
TOTAL ASSETS
Total Short-Term Assets $385.4M $411.6M $431.4M
Total Long-Term Assets $196.5M $202.4M $131.7M
Total Assets $581.9M $613.9M $563.1M
YoY Change 11.18% 9.03% 21.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.745M $6.483M $2.567M
YoY Change 57.75% 152.55% -69.07%
Accrued Expenses $22.49M $18.50M $20.78M
YoY Change 3.46% -10.95% 59.82%
Deferred Revenue $24.30M $32.25M $60.85M
YoY Change -59.13% -47.01%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.231M $1.339M $1.087M
YoY Change 6.3% 23.18% 81.17%
Total Short-Term Liabilities $54.60M $61.93M $88.34M
YoY Change -37.6% -29.89% -19.79%
LONG-TERM LIABILITIES
Long-Term Debt $762.0K $989.0K $927.0K
YoY Change -17.8% 6.69% 85.4%
Other Long-Term Liabilities $230.0K $237.0K $273.0K
YoY Change -12.88% -13.19% 196.74%
Total Long-Term Liabilities $230.0K $237.0K $273.0K
YoY Change -12.88% -13.19% 196.74%
TOTAL LIABILITIES
Total Short-Term Liabilities $54.60M $61.93M $88.34M
Total Long-Term Liabilities $230.0K $237.0K $273.0K
Total Liabilities $146.5M $151.9M $134.3M
YoY Change 16.77% 13.07% -29.04%
SHAREHOLDERS EQUITY
Retained Earnings -$463.5M -$424.7M -$265.7M
YoY Change 51.52% 59.84% 87.32%
Common Stock $902.6M $889.8M $697.6M
YoY Change 27.51% 27.55% 67.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $435.4M $462.0M $428.7M
YoY Change
Total Liabilities & Shareholders Equity $581.9M $613.9M $563.1M
YoY Change 11.18% 9.03% 21.2%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$38.80M -$40.93M -$36.68M
YoY Change -3.62% 11.57% 180.57%
Depreciation, Depletion And Amortization $900.0K $879.0K $687.0K
YoY Change 28.57% 27.95% 41.65%
Cash From Operating Activities -$35.26M -$43.97M -$40.30M
YoY Change -9.57% 9.12% 76.55%
INVESTING ACTIVITIES
Capital Expenditures $10.77M $4.009M $482.0K
YoY Change -1565.03% 731.74% 193.9%
Acquisitions
YoY Change
Other Investing Activities $46.61M $28.59M $26.35M
YoY Change -43.53% 8.53% -40.8%
Cash From Investing Activities $35.84M $24.58M $25.86M
YoY Change -56.19% -4.95% -41.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.305M 1.159M 185.0K
YoY Change 258.52% 526.49% -68.91%
NET CHANGE
Cash From Operating Activities -35.26M -43.97M -40.30M
Cash From Investing Activities 35.84M 24.58M 25.86M
Cash From Financing Activities 1.305M 1.159M 185.0K
Net Change In Cash 1.888M -18.23M -14.25M
YoY Change -95.63% 27.92% -164.48%
FREE CASH FLOW
Cash From Operating Activities -$35.26M -$43.97M -$40.30M
Capital Expenditures $10.77M $4.009M $482.0K
Free Cash Flow -$46.02M -$47.98M -$40.78M
YoY Change 20.32% 17.66% 77.39%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Change In Accounting Principle Accounting Standards Update Immaterial Effect
ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
true
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8909000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3155000
CY2022Q2 us-gaap Change In Accounting Principle Accounting Standards Update Adopted
ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
true
kymr Net Operating Loss Carryforwards Period Cares Act
NetOperatingLossCarryforwardsPeriodCARESAct
P5Y
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#RevenueFromRelatedParties
CY2022Q1 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#RevenueFromRelatedParties
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001815442
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-39460
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
KYMERA THERAPEUTICS, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-2992166
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
200 Arsenal Yards Blvd
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 230
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
CY2023Q1 dei City Area Code
CityAreaCode
857
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
285-5300
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
KYMR
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
55307775
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50152000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68395000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
346725000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
338771000
CY2023Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
3320000
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
2537000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11353000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9713000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
411550000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
419416000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
119017000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
152328000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17432000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13334000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
56604000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3017000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
6147000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
6130000
CY2023Q1 us-gaap Assets
Assets
613905000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9622000
CY2022Q4 us-gaap Assets
Assets
603134000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
6483000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4335000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18502000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27502000
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
32248000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
35260000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2554000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2535000
CY2023Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1339000
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1408000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
807000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
303000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
61933000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
71343000
CY2023Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
24866000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
28000000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
63875000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12146000
CY2023Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
989000
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1246000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
237000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
248000
CY2023Q1 us-gaap Liabilities
Liabilities
151900000
CY2022Q4 us-gaap Liabilities
Liabilities
112983000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55276226
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55276226
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55039380
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55039380
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
6000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
889755000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
878884000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-424718000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-383790000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3038000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4949000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
462005000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
490151000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
613905000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
603134000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9466000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42227000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35944000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12565000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10611000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
54792000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
586000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
46555000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-45326000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-36933000
CY2023Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
4453000
CY2022Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
290000
CY2023Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
55000
CY2022Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
41000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4398000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
249000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-40928000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-36684000
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1911000
CY2022Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-2556000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39017000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39240000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-40928000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-36684000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.70
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58187038
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58187038
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51651125
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51651125
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
459638000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
449000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7873000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2556000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-36684000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
428720000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
490151000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1486000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9385000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1911000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-40928000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
462005000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-40928000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-36684000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
9385000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
7873000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
879000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
687000
CY2023Q1 kymr Premiums And Discounts On Available For Sale Marketable Securities
PremiumsAndDiscountsOnAvailableForSaleMarketableSecurities
-1326000
CY2022Q1 kymr Premiums And Discounts On Available For Sale Marketable Securities
PremiumsAndDiscountsOnAvailableForSaleMarketableSecurities
1175000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1641000
CY2023Q1 kymr Increase Decrease In Contract With Customer Asset Related Parties
IncreaseDecreaseInContractWithCustomerAssetRelatedParties
783000
CY2022Q1 kymr Increase Decrease In Contract With Customer Asset Related Parties
IncreaseDecreaseInContractWithCustomerAssetRelatedParties
-1128000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2217000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1437000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-10037000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2278000
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-6145000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-8359000
CY2023Q1 kymr Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-1138000
CY2022Q1 kymr Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-119000
CY2023Q1 kymr Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
2915000
CY2022Q1 kymr Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-227000
CY2023Q1 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-358000
CY2022Q1 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-550000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43968000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40295000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4009000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
482000
CY2023Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
61835000
CY2022Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
80118000
CY2023Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
90428000
CY2022Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
106463000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
24584000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
25863000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1486000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
449000
CY2023Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
327000
CY2022Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
264000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1159000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
185000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18225000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14247000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
74524000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
54092000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
56299000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
39845000
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
48833000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
52000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
46000
CY2023Q1 kymr Property And Equipment Purchases Included In Accounts Payable And Accrued Expenses
PropertyAndEquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses
1100000
CY2022Q1 kymr Property And Equipment Purchases Included In Accounts Payable And Accrued Expenses
PropertyAndEquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses
126000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50152000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33733000
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
6147000
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
6112000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
56299000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
39845000
CY2022Q4 kymr Fair Value Assets Level2 To Level3 Transfers Amount
FairValueAssetsLevel2ToLevel3TransfersAmount
0
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-424700000
CY2023Q1 us-gaap Investments And Cash
InvestmentsAndCash
515900
CY2023Q1 kymr Fair Value Assets Level1 To Level3 Transfers Amount
FairValueAssetsLevel1ToLevel3TransfersAmount
0
CY2022Q4 kymr Fair Value Assets Level1 To Level3 Transfers Amount
FairValueAssetsLevel1ToLevel3TransfersAmount
0
CY2023Q1 kymr Fair Value Assets Level3 To Level1 Transfers Amount
FairValueAssetsLevel3ToLevel1TransfersAmount
0
CY2022Q4 kymr Fair Value Assets Level3 To Level1 Transfers Amount
FairValueAssetsLevel3ToLevel1TransfersAmount
0
CY2023Q1 kymr Fair Value Assets Level3 To Level2 Transfers Amount
FairValueAssetsLevel3ToLevel2TransfersAmount
0
CY2022Q4 kymr Fair Value Assets Level3 To Level2 Transfers Amount
FairValueAssetsLevel3ToLevel2TransfersAmount
0
CY2023Q1 kymr Fair Value Assets Level2 To Level3 Transfers Amount
FairValueAssetsLevel2ToLevel3TransfersAmount
0
CY2023Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
468777000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
177000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3212000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
465742000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
496044000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
53000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4998000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
491099000
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
130
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
291700000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
149
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
330900000
CY2023Q1 kymr Debt Securities Available For Sale Decline In Market Value For Unrealized Loss Position Number Of Securities
DebtSecuritiesAvailableForSaleDeclineInMarketValueForUnrealizedLossPositionNumberOfSecurities
38
CY2023Q1 kymr Debt Securities Available For Sale Continuous Unrealized Loss Position Greater Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionGreaterThan12Months
102500000
CY2022 kymr Debt Securities Available For Sale Decline In Market Value For Unrealized Loss Position Number Of Securities
DebtSecuritiesAvailableForSaleDeclineInMarketValueForUnrealizedLossPositionNumberOfSecurities
36
CY2022Q4 kymr Debt Securities Available For Sale Continuous Unrealized Loss Position Greater Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionGreaterThan12Months
115000000.0
CY2023Q1 kymr Debt Securities Available For Sale Contractual Maturity Of Less Than12 Months Number Of Securities
DebtSecuritiesAvailableForSaleContractualMaturityOfLessThan12MonthsNumberOfSecurities
139
CY2023Q1 kymr Fair Value Of Available For Sale Debt Securities Contractual Maturity Of Less Than Twelve Months
FairValueOfAvailableForSaleDebtSecuritiesContractualMaturityOfLessThanTwelveMonths
346700000
CY2023Q1 kymr Debt Securities Available For Sale Contractual Maturity Of12 Months Or Longer Number Of Securities
DebtSecuritiesAvailableForSaleContractualMaturityOf12MonthsOrLongerNumberOfSecurities
61
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
119000000.0
CY2022 kymr Debt Securities Available For Sale Contractual Maturity Of Less Than12 Months Number Of Securities
DebtSecuritiesAvailableForSaleContractualMaturityOfLessThan12MonthsNumberOfSecurities
118
CY2022Q4 kymr Fair Value Of Available For Sale Debt Securities Contractual Maturity Of Less Than Twelve Months
FairValueOfAvailableForSaleDebtSecuritiesContractualMaturityOfLessThanTwelveMonths
338800
CY2022 kymr Debt Securities Available For Sale Contractual Maturity Of12 Months Or Longer Number Of Securities
DebtSecuritiesAvailableForSaleContractualMaturityOf12MonthsOrLongerNumberOfSecurities
81
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
152300000
CY2023Q1 us-gaap Availableforsale Securities Sold At Par
AvailableforsaleSecuritiesSoldAtPar
0
CY2022Q1 us-gaap Availableforsale Securities Sold At Par
AvailableforsaleSecuritiesSoldAtPar
0
CY2023Q1 kymr Available For Sale Securities Credit Losses
AvailableForSaleSecuritiesCreditLosses
0
CY2022Q4 kymr Available For Sale Securities Credit Losses
AvailableForSaleSecuritiesCreditLosses
0
CY2023Q1 kymr Cost Reimbursement Payment Received
CostReimbursementPaymentReceived
2500000
CY2023Q1 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
3300000
CY2023Q1 kymr Remaining Research Term Of Collaboration
RemainingResearchTermOfCollaboration
P2Y9M18D
CY2022Q4 us-gaap Contract With Customer Receivable After Allowance For Credit Loss
ContractWithCustomerReceivableAfterAllowanceForCreditLoss
2537000
CY2023Q1 kymr Contract With Customer Asset Net Additions
ContractWithCustomerAssetNetAdditions
5857000
CY2023Q1 kymr Contract With Customer Asset Net Deductions
ContractWithCustomerAssetNetDeductions
5074000
CY2023Q1 us-gaap Contract With Customer Receivable After Allowance For Credit Loss
ContractWithCustomerReceivableAfterAllowanceForCreditLoss
3320000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
63260000
CY2023Q1 kymr Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
3320000
CY2023Q1 kymr Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
-9466000
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
57114000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25223000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
20227000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7791000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6893000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17432000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13334000
CY2023Q1 us-gaap Depreciation
Depreciation
900000
CY2022Q1 us-gaap Depreciation
Depreciation
700000
CY2023Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
400000
CY2022Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
300000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
2521000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
524000
CY2023Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
369000
CY2022Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
279000
CY2023Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
52000
CY2022Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
46000
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
220000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
329000
CY2023Q1 us-gaap Lease Cost
LeaseCost
3162000
CY2022Q1 us-gaap Lease Cost
LeaseCost
1178000
CY2023Q1 kymr Operating Lease Payments Proceeds
OperatingLeasePaymentsProceeds
651000
CY2022Q1 kymr Operating Lease Payments Proceeds
OperatingLeasePaymentsProceeds
631000
CY2023Q1 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
327000
CY2022Q1 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
264000
CY2023Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
52000
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
46000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y9M
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y1M2D
CY2023Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M29D
CY2022Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y1M6D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0887
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1050
CY2023Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0852
CY2022Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0875
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
15639000
CY2023Q1 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
1084000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
11482000
CY2023Q1 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
839000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
12142000
CY2023Q1 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
402000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
12506000
CY2023Q1 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
133000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
12881000
CY2023Q1 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
100000
CY2023Q1 kymr Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
85143000
CY2023Q1 kymr Finance Lease Liability Payments Due After Year Four
FinanceLeaseLiabilityPaymentsDueAfterYearFour
0
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
118515000
CY2023Q1 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
2558000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
52086000
CY2023Q1 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
230000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
66429000
CY2023Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
2328000
CY2023Q1 kymr Undiscounted Future Lease Payments
UndiscountedFutureLeasePayments
17600000
CY2023Q1 kymr Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
11097000
CY2022Q4 kymr Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
16975000
CY2023Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
3592000
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
8149000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2287000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1971000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1526000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
407000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18502000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27502000
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M25D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M21D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.62
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.62
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0414
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0159
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9385000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7873000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-40928000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-36684000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58187038
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58187038
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51651125
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51651125
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.70
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8744452
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7241028

Files In Submission

Name View Source Status
0000950170-23-017462-index-headers.html Edgar Link pending
0000950170-23-017462-index.html Edgar Link pending
0000950170-23-017462.txt Edgar Link pending
0000950170-23-017462-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
kymr-20230331.htm Edgar Link pending
kymr-20230331.xsd Edgar Link pending
kymr-ex31_1.htm Edgar Link pending
kymr-ex31_2.htm Edgar Link pending
kymr-ex32_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
kymr-20230331_cal.xml Edgar Link unprocessable
kymr-20230331_def.xml Edgar Link unprocessable
kymr-20230331_pre.xml Edgar Link unprocessable
kymr-20230331_lab.xml Edgar Link unprocessable
kymr-20230331_htm.xml Edgar Link completed
kymr-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending